The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Awesome research guys. Someone has said before VELA need a PR team... never more needed than now. Got Peterhouse capital giving us more exposure than VELA at the moment!
Completely agree, thanks guys.
Credit should go to DShox & solstace for highlighting these articles in the first instance this morning. Adding great value to the BB, thks.
I found that this article was a lot clearer in terms of the findings, potential for the treatment and the path forward than the RNS itself. Goes some way to explain the SP movement and the little negativity we are seeing.
It has gone way beyond just diabetes now, "They also hope to trial the drug in people without diabetes potentially benefiting an even larger group of people such as patients with long Covid." Global Market just expanded exponentially.
Nice find Dave
I would like to emphasise this line as this should be your stock standard reply to anyone trying to claim that several days of waiting indicates a problem -
'promising finding which will need to be analyzed further by the researchers, when cellular immunology results become available, before the study results undergo peer review.'
Good find BD. I find this to be the salient line 'The trial reduced the number of deaths in patients receiving AZD1656, a promising finding which will need to be analyzed further by the researchers, when cellular immunology results become available, before the study results undergo peer review.' which explains the delay somewhat. And this bit is totally exciting: Professor Martin, Chairman of SGSC and Principal Investigator on the UKRI grant said that "we have demonstrated our ability to rapidly deliver a clinical trial in 16 months from conception to completion. The promising results from this trial indicate that AZD1656, a simple oral tablet, has the potential to become a new treatment for COVID-19. It is beneficial regardless of viral mutations. It is the first specific treatment for COVID disease (as opposed to antivirals or vaccines) and may herald a new field of drugs activating cells in the body which become themselves the therapeutic agent."
Nomad spreading the word as well
https://twitter.com/peterhousecap/status/1440257172420526085
End of Sept or soon thereafter would be amazing. What else do we have to look forward to in the short term:
-Accounts by 30 Sept
-NED appointment
-Next Investment with Cash balance c. £2.4m
-Commercial Deal
Added to that you’d hope due to the immediate need everything being worked is at optimum speed.
I’ll stand by my initial prediction we’ll get positive news by month end.
I guess it also depends on the size of the trial. Considering this was 'only' 158 patients a peer review shouldn't take too long.
How long does a medical peer review take?
The usual recommended time for a review is two to four weeks
Source: Google
My ISA is maxed out. Considering buying more in trading account, then bed & ISA next April. Gla.
You can't go higher than No10 that's for sure. Come on Vela re-rate. ATB.
Good work Solstace, BoJo won't be able to contain himself much longer, another win for UK! May need the further analysis and peer review b4 commercialisation but either way, can't be too long now. Imagine when this hits the main media.
ps, can we ignore trolls today, let's focus on this amazing news.
Cheers for sharing the couple of links Solstace.
Always good to read factual, printed information.
Seems the media outlets are gathering some momentum on ARCADIA, hopefully it generates more people taking substantial positions with VELA.
Secondly there's no reason we should be dipping any lower than where we've found ourselves - warrants dealt with, SGS shares placed and twitter traders gone. Have some courage of conviction as to why you bought in here and hold.
Mubadala, JN, Sir Chris Evans - C'mon now there's no pretenders there.
Great find thanks for sharing. Gla